Pre-made Rituximab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Rituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein-CBarr virus-positive mucocutaneous ulcers. It is given by slow injection into a vein.
| Products Name (INN Index) | Pre-Made Rituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
|---|---|
| INN Name | Rituximab |
| Target | MS4A1 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 2osl:HL:AB |
| 99% SI Structure | 4kaq:HL |
| 95-98% SI Structure | None |
| Year Proposed | 1997 |
| Year Recommended | 1998 |
| Conditions Approved | Chronic lymphocytic leukaemia,Diffuse large B cell lymphoma,Follicular lymphoma,Idiopathic thrombocytopenic purpura,Lymphoproliferative disorders,Microscopic polyangiitis,Nephrotic syndrome,Non-Hodgk |
| Conditions Active | Mantle-cell lymphoma,Transplant rejection,Neuromyelitis optica,B-cell lymphoma,Chronic inflammatory demyelinating polyradiculoneuropathy,Glomerulonephritis,Precursor cell lymphoblastic leukaemia-lymp |
| Conditions Discontinued | Multiple sclerosis,Ocular inflammation,Primary biliary cirrhosis,Scleritis,Sjogren's syndrome,Ulcerative colitis,Dermatomyositis,Graft-versus-host disease,Lupus nephritis,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MS4A1 |
| Package |
